While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition ... which is available in vial form or as a disposable pen. Sanofi fights back This represents Sanofi's first foray into ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the ...